GB Patent

GB2610100B — Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases

Assigned to Stoke Therapeutics Inc · Expires 2023-08-16 · 3y expired

What this patent protects

Patent listed against nusinersen-sodium.

Drugs covered by this patent

nusinersen-sodium (NUSINERSEN SODIUM)

Patent Metadata

Patent number: GB2610100B
Jurisdiction: GB
Classification: —
Expires: 2023-08-16
Drug substance claim: No
Drug product claim: No
Assignee: Stoke Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.